Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitisFilomena Russo, Massimo Gola, Angelo Massimiliano D’Erme et al.|Giornale Italiano di Dermatologia e Venereologia|2020Cited by 16
Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areasAngela Michelucci, M. Romanelli, Flavia Manzo Margiotta et al.|Archives of Dermatological Research|2024Cited by 5
Risankizumab in Oncologic Patients With Psoriasis: A Case SeriesMichela Magnano, Francesca Prignano, Susanna Rossari et al.|JEADV Clinical Practice|2024Cited by 3
Risankizumab in very elderly patients in real-world practiceE Lorenzoni, Francesca Prignano, Antonella Di Cesare et al.|Italian Journal of Dermatology and Venereology|2024Cited by 2
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective StudyAntonella Di Cesare, Francesca Prignano, Elia Rosi et al.|Dermatology Practical & Conceptual|2025Cited by 1